Clinical trial • Phase II • Endocrinology
EXENATIDE for Gestational diabetes
Phase II trial of EXENATIDE for Gestational diabetes. 24 participants.
Overview
- Trial Therapeutic Area
- Endocrinology
- Trial Disease
- Gestational diabetes
- Trial Stage
- Phase II
- Drug Modality
- Peptide/protein/enzyme|Radiopharmaceutical
Key dates
- Initial CTIS Submission Date
- 20-12-2024
- First CTIS Authorization Date
- 13-01-2025
Trial design
Phase II trial across 1 site in Netherlands.
- Target Sample Size
- 24
Eligibility
Recruits 24 Vulnerable population not selected (isVulnerablePopulationSelected: false). Participants must provide signed informed consent (inclusion: "Signed informed consent"; exclusion: "no signed informed consent"). Minors are excluded (exclusion: "Age < 18 years"). No assent process described..
- Pregnancy Exclusion
- Current pregnancy or the wish to become pregnant within 6 months
- Vulnerable Population
- Vulnerable population not selected (isVulnerablePopulationSelected: false). Participants must provide signed informed consent (inclusion: "Signed informed consent"; exclusion: "no signed informed consent"). Minors are excluded (exclusion: "Age < 18 years"). No assent process described.
Inclusion criteria
- {"criterion_text":"- Pregnancy with diagnosis of GDM, within the last 5 years"}
- {"criterion_text":"- No other previous pregnancies"}
- {"criterion_text":"- Complete resolution of GDM after delivery (HbAlc in normal range, fasting glucose < 1OO mg/dl for at least I year in the absence of active pharmacologic therapy or ongoing procedures)"}
- {"criterion_text":"- Signed informed consent"}
Exclusion criteria
- {"criterion_text":"- Previous treatment (within 6 months) with synthetic Exendin (Exenatide, Byetta@) or Dipeptidyl-Peptidase IV inhibitors"}
- {"criterion_text":"- Breast feeding"}
- {"criterion_text":"- Current pregnancy or the wish to become pregnant within 6 months"}
- {"criterion_text":"- Renal dysfunction (Calculated creatinine clearance below 40 ml/min)"}
- {"criterion_text":"- Liver disease defined as aspartate aminotransferase or alan¡ne aminotransferase level of more than three times the upper limit of normal range"}
- {"criterion_text":"- Age < 18 years"}
- {"criterion_text":"- incapacitated"}
- {"criterion_text":"- no signed informed consent"}
Endpoints
Primary endpoints
- {"endpoint_text":"- The main parameter of the study is the quantitative assessment of pancreatic 68Ga-NODAGA-exendin-4 uptake women with and without a history of GDM by PET/CT.","definition_or_measurement_approach":"Quantitative assessment of 68Ga-NODAGA-exendin-4 tracer accumulation in the pancreas by PET/CT imaging (quantitative analysis of PET images)."}
Secondary endpoints
- {"endpoint_text":"- The correlation between Ga-exendin tracer accumulation and beta cell function of the subjects","definition_or_measurement_approach":"Correlation between tracer accumulation (PET imaging) and beta cell function as assessed by oral glucose tolerance testing (OGTT)."}
Recruitment
- Planned Sample Size
- 24
- Recruitment Window Months
- 12
- Consent Approach
- Signed informed consent is required (inclusion criterion: "Signed informed consent"). Separate subject information and informed consent forms exist for women with and without GDM (documents: L1_SIS_ICF_women_with_GDM; L1_SIS_ICF_women_without_GDM). No assent process or age-specific consent procedures described. Language availability not specified (trial translations include Dutch).
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 24
Netherlands
- Earliest CTIS Part Ii Submission Date
- 09-01-2025
- Latest Decision Or Authorization Date
- 13-01-2025
- Processing Time Days
- 4
- Number Of Sites
- 1
- Number Of Participants
- 24
Sites
- Site Name
- Radboud universitair medisch centrum Stichting
- Department Name
- Nuclear Medicine
- Contact Person Name
- Martin Gotthardt
- Contact Person Email
- martin.gotthardt@radboudumc.nl
Sponsor
Primary sponsor
- Full Name
- Radboud universitair medisch centrum Stichting
- Organisation Type
- Hospital/Clinic/Other health care facility
- Country Of Registered Address
- Netherlands
Investigational products
- Investigational Product Name
- EXENATIDE
- Active Substance
- EXENATIDE
- Modality
- Peptide/protein/enzyme|Radiopharmaceutical
- Routes Of Administration
- INTRAVENOUS BOLUS INJECTION/IV INFUSION
- Route
- INTRAVENOUS BOLUS INJECTION/IV INFUSION
- Authorisation Status
- marketingAuthNumber: -; prodAuthStatus: 2
- Maximum Dose
- 150 MBq
Related trials
Other published trials that may interest you.